PMID- 29204993
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20240124
IS  - 2162-0989 (Electronic)
IS  - 2162-0989 (Linking)
VI  - 6
IP  - 6
DP  - 2017 Nov-Dec
TI  - Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein 
      Occlusions.
PG  - 546-553
LID - 10.22608/APO.2017459 [doi]
AB  - The use of anti-vascular endothelial growth factor (VEGF) therapy in 
      ophthalmology has profoundly changed our management and treatment of conditions 
      such as cystoid macular edema, diabetic macular edema, choroidal 
      neovascularization, and other proliferative retinopathies. Although initially 
      used for the treatment of choroidal neovascularization in neovascular age-related 
      macular degeneration, their application has spread rapidly for other indications 
      as their outcomes have often outperformed previously existing treatments. Retinal 
      vein occlusion (RVO) continues to be one of the leading causes of vision loss 
      secondary to macular edema, in addition to macular ischemia and 
      neovascularization in more severe cases. Before the availability of anti-VEGF 
      therapy, the use of macular grid laser and panretinal photocoagulation was the 
      mainstay of treatment of macular edema and neovascularization, respectively, in 
      patients with RVOs. Two landmarks studies established the guidelines of these 
      treatments for nearly a quarter century. Since the availability of anti-VEGF 
      agents, there has been a paradigm shift in the treatment of RVO. Most 
      importantly, there has also been a significant improvement in visual outcomes in 
      these patients. The goal of this article is to provide a review of the pertinent 
      clinical studies that have investigated the use of anti-VEGF in patients with 
      retinal vein occlusions.
CI  - Copyright 2017 Asia-Pacific Academy of Ophthalmology.
FAU - Jiang, Yi
AU  - Jiang Y
AD  - University of Illinois at Chicago, Chicago, IL, United States.
FAU - Mieler, William F
AU  - Mieler WF
AD  - University of Illinois at Chicago, Chicago, IL, United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Asia Pac J Ophthalmol (Phila)
JT  - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
JID - 101583622
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Bevacizumab/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/drug therapy
MH  - Ranibizumab/therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/therapeutic use
MH  - Recombinant Fusion Proteins/therapeutic use
MH  - Retinal Vein Occlusion/*drug therapy
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
OTO - NOTNLM
OT  - anti-VEGF intravitreal therapies
OT  - retinal vein occlusions
EDAT- 2017/12/06 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/10/30 00:00 [received]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/06 06:00 [entrez]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - S2162-0989(23)00430-9 [pii]
AID - 10.22608/APO.2017459 [doi]
PST - ppublish
SO  - Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):546-553. doi: 
      10.22608/APO.2017459.